Our company was founded to solve the significant yet unmet needs in vascular access. After shadowing physicians and learning about the challenge that thrombosis presents to vascular access, our founders set off to develop a new, groundbreaking biomaterial that is fundamentally different than the polyurethane used in conventional vascular catheters. Our foundationally unique, thrombus-evading catheters alleviate the clinical and economic burden from vascular access complications, so focus can remain on outcomes.

In 2018, we secured FDA clearance on our first product, a peripherally inserted central catheter (PICC) which was found to be effective in reducing thrombosis accumulation. In 2021, we received our second FDA clearance with the HydroMID a peripherally inserted midline catheter which has demonstrated 6x fewer complications then a standard polyurethane catheter.**

We are a privately held company based in Billerica, MA. Our headquarters consists of a 40,000 square foot facility that includes state-of-the-art laboratory and manufacturing spaces. We employ approximately 40 employees and our products are commercially available in the United States.

Access Vascular is committed to providing our customers with the highest quality intravascular products that meet or exceed expectations. Access Vascular commits to comply with the necessary requirements and regulations through the regular maintenance of an effective quality system and seeks to continuously improve its products.